Logo
Paradigm Biopharmaceuticals

Osteoarthritis

Paradigm is developing injectable pentosan polysulfate sodium, Zilosul®, for knee osteoarthritis. It is a molecule with decades of existing safety data, for a disease where no available treatment alters its course, and it is in Phase 3 with an independent interim analysis targeted for September 2026.

Phase 3 Development Program

PARA_OA_012 is a multicentre, randomised, double-blind, placebo-controlled study of injectable pentosan polysulfate sodium in knee osteoarthritis. It is fully enrolled and closed to new participants.

Participants dosed 538 Against a 466 target.
Clinical sites 57  
Countries 4 Australia, US, Hong Kong, Moldova.
Status
Fully enrolled, closed to new participants
Study code
PARA_OA_012
Registry
NCT06917404
Design
Multicentre, randomised, double-blind, placebo-controlled
Primary endpoint
Change from baseline in weekly average pain at Day 112
Designation
FDA Fast Track, April 2022

Milestones

The next milestone is an independent interim analysis, targeted for September 2026. Following database lock, a Data Safety Monitoring Board reviews the accumulated data. An earlier safety review of approximately 20% of completed participants identified no material safety concerns and recommended the trial continue without changes.

  1. Oct 2021 IND cleared by the US FDA Complete
  2. Apr 2022 FDA Fast Track designation Complete
  3. May 2025 First participant dosed Complete
  4. Jun 2026 Enrolment complete, 538 participants dosed Complete
  5. Next Sep 2026 Independent interim analysis Targeted
  6. Q1 2027 Topline results Expected

Key osteoarthritis figures

Prevalence 595M+ Global prevalence People living with osteoarthritis worldwide.
  • GLOBAL
Site of disease 69% Knee and hip Of all osteoarthritis is knee and hip.
Unmet need 81% Patients dissatisfied Of patients are dissatisfied with available treatments.

Following the osteoarthritis programme

Paradigm’s Phase 3 trial is fully enrolled and closed to new participants. Paradigm is not recruiting for any osteoarthritis trial at this time, and cannot discuss individual eligibility or any matter relating to your condition. Your own doctor is the right person to talk to about treatment options.

Trial details are published in full on the registries, and every milestone is announced to the ASX.